indication

Central Nervous System Diseases

Competitive landscape

as of 2026-07-01
Competitive set
1
0 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
0 events
2024
2026
2028
2030
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Flupentixol
Pipeline · Phase 4
Phase 41 trial
OwnerTechnical University of Munich
Protection—

Market size

prevalence as a range, not a number